(function(){var loadHandler=window['sl_{70F84434-E230-4897-A900-6C791B0E8453}'];loadHandler&&loadHandler(6, '<div id="spr0_52e6d181"><div id="spr1_52e6d181" class="kern slide"><img id="img9_52e6d181" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_52e6d181" class="kern slide"><img id="img0_52e6d181" src="data/img2.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_52e6d181" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_52e6d181" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_52e6d181" src="data/img3.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_52e6d181" style="left:657.715px;top:499.855px;"><img id="img2_52e6d181" src="data/img4.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_52e6d181" style="left:0px;top:7.56px;"><div style="width:0px;"><span id="txt0_52e6d181" data-width="659.285156" style="left:30.437px;top:5.272px;">Non-Statin Strategies to Further Reduce LDL-C</span></div><div style="width:0px;"><span id="txt1_52e6d181" data-width="224.979385" style="left:252.877px;top:48.171px;">PCSK9 Inhibitors</span></div></div><div id="spr5_52e6d181" style="left:7.591px;top:503.997px;"><div style="width:0px;"><span id="txt2_52e6d181" class="nokern" data-width="164.948730" style="left:7.2px;top:4.096px;">Sebatine MS, N Engl J Med. 2017;376:1713-1722;</span></div><div style="width:0px;"><span id="txt3_52e6d181" class="nokern" data-width="182.583984" style="left:7.2px;top:14.896px;">Schwartz GG, et al. N Engl J Med. 2018;379:2097-2107</span></div></div><div id="spr6_52e6d181" style="left:511.316px;top:138.138px;"><div style="width:0px;"><span id="txt4_52e6d181" data-width="140.238281" style="left:21.51px;top:4.436px;">Adding ezetimibe to</span></div><div style="width:0px;"><span id="txt5_52e6d181" data-width="101.698242" style="left:40.76px;top:26.036px;">statin therapy:</span></div><div style="width:0px;"><span id="txt6_52e6d181" class="nokern relpos" style="left:7.2px;top:69.649px;"></span><span id="txt7_52e6d181" class="relpos" data-width="99.171875" style="left:22.38px;top:69.282px;">Additional LDL-C</span></div><div style="width:0px;"><span id="txt8_52e6d181" data-width="134.960938" style="left:29.7px;top:88.482px;">reduction of about 20%</span></div><div style="width:0px;"><span id="txt9_52e6d181" class="nokern relpos" style="left:7.2px;top:127.249px;"></span><span id="txt10_52e6d181" class="relpos" data-width="112.312500" style="left:22.38px;top:126.882px;">6% reduction in CV</span></div><div style="width:0px;"><span id="txt11_52e6d181" data-width="38.664063" style="left:29.7px;top:146.082px;">events</span></div></div><div id="spr7_52e6d181" style="left:7px;top:118px;"><div style="width:0px;"><span id="txt12_52e6d181" data-width="621.164063" style="left:42.397px;top:15.581px;">PCSK9 inhibitors further reduce LDL-C by an average of 50 to 60%</span></div></div><div id="spr8_52e6d181" style="left:7px;top:118px;"><img id="img3_52e6d181" src="data/img14.png" width="709" height="59" alt=""/></div><div id="spr9_52e6d181" style="left:7px;top:118px;"><div style="width:0px;"><span id="txt13_52e6d181" data-width="621.164063" style="left:40.275px;top:17.702px;">PCSK9 inhibitors further reduce LDL-C by an average of 50 to 60%</span></div></div><div id="svg4_52e6d181" style="left:7.591px;top:182.497px;"><svg width="702" height="141" viewBox="0 0 702 141"><path fill="#525f83" fill-opacity="0.2" d="M0,0 h701.243 v140.559 h-701.243 Z"/></svg></div><div id="spr10_52e6d181" style="left:7.591px;top:182.497px;"><div style="width:0px;"><span id="txt14_52e6d181" class="nokern relpos" style="left:7.2px;top:5.841px;"></span><span id="txt15_52e6d181" class="relpos" data-width="263.466797" style="left:20.55px;top:5.382px;">Further reduce the risk of CV events</span></div><div style="width:0px;"><span id="txt16_52e6d181" class="nokern relpos" style="left:7.2px;top:35.841px;"></span><span id="txt17_52e6d181" class="relpos" data-width="599.453125" style="left:20.55px;top:35.382px;">CV benefits are proportional to the absolute reduction in LDL-C and the duration of</span></div><div style="width:0px;"><span id="txt18_52e6d181" data-width="69.287109" style="left:29.7px;top:59.382px;">treatment</span></div><div style="width:0px;"><span id="txt19_52e6d181" class="nokern relpos" style="left:7.2px;top:89.841px;"></span><span id="txt20_52e6d181" class="relpos" data-width="629.101563" style="left:20.55px;top:89.382px;">Greatest benefit reported in patients with additional high-risk factors such as recent MI,</span></div><div style="width:0px;"><span id="txt21_52e6d181" data-width="274.404297" style="left:29.7px;top:113.382px;">polyvascular disease, prior CV events</span></div></div><div id="spr11_52e6d181" style="left:199.89px;top:383.981px;"><img id="img4_52e6d181" src="data/img15.png" width="72" height="72" alt="Man"/></div><div id="spr12_52e6d181" style="left:245.583px;top:335.519px;"><img id="img5_52e6d181" src="data/img16.png" width="72" height="72" alt="Woman"/></div><div id="spr13_52e6d181" style="left:288px;top:383.981px;"><img id="img6_52e6d181" src="data/img17.png" width="72" height="72" alt="Woman"/></div><div id="spr14_52e6d181" style="left:245.583px;top:423.746px;"><img id="img7_52e6d181" src="data/img18.png" width="72" height="72" alt="Man"/></div><div id="spr15_52e6d181" style="left:272.214px;top:352.513px;"><div style="width:0px;"><span id="txt22_52e6d181" style="left:5.433px;top:4.343px;">?</span></div></div><div id="spr16_52e6d181" style="left:314.603px;top:400.743px;"><div style="width:0px;"><span id="txt23_52e6d181" style="left:5.433px;top:4.343px;">?</span></div></div><div id="spr17_52e6d181" style="left:271.829px;top:440.113px;"><div style="width:0px;"><span id="txt24_52e6d181" style="left:5.433px;top:4.343px;">?</span></div></div><div id="spr18_52e6d181" style="left:226.777px;top:400.15px;"><div style="width:0px;"><span id="txt25_52e6d181" style="left:5.433px;top:4.343px;">?</span></div></div><div id="spr19_52e6d181" style="left:366px;top:326px;"><div style="width:0px;"><span id="txt26_52e6d181" data-width="143.125000" style="left:21.584px;top:24.513px;">The real challenge</span></div><div style="width:0px;"><span id="txt27_52e6d181" data-width="133.964844" style="left:26.144px;top:48.513px;">now is to identify</span></div><div style="width:0px;"><span id="txt28_52e6d181" data-width="165.869141" style="left:10.209px;top:72.513px;">which patients would</span></div><div style="width:0px;"><span id="txt29_52e6d181" data-width="138.496094" style="left:23.709px;top:96.513px;">benefit most from</span></div><div style="width:0px;"><span id="txt30_52e6d181" data-width="133.945313" style="left:26.019px;top:120.513px;">PCSK9 inhibitors</span></div></div><div id="spr20_52e6d181" style="left:366px;top:326px;"><img id="img8_52e6d181" src="data/img19.png" width="189" height="169" alt=""/></div><div id="spr21_52e6d181" style="left:366px;top:326px;"><div style="width:0px;"><span id="txt31_52e6d181" data-width="143.125000" style="left:19.463px;top:26.634px;">The real challenge</span></div><div style="width:0px;"><span id="txt32_52e6d181" data-width="133.964844" style="left:24.023px;top:50.634px;">now is to identify</span></div><div style="width:0px;"><span id="txt33_52e6d181" data-width="165.869141" style="left:8.088px;top:74.634px;">which patients would</span></div><div style="width:0px;"><span id="txt34_52e6d181" data-width="138.496094" style="left:21.588px;top:98.634px;">benefit most from</span></div><div style="width:0px;"><span id="txt35_52e6d181" data-width="133.945313" style="left:23.898px;top:122.634px;">PCSK9 inhibitors</span></div></div></div></div>');})();